Vol. 7, Issue 1, Part A (2025)

The prevalence of respiratory diseases has driven significant interest in inhalable nanoparticle-based pharmaceutical formulations. These innovative treatments offer a promising approach for next-generation respiratory therapies. Traditional methods for managing lung diseases, such as oral medications, injectables, nebulizers, and aerosols, often require frequent administration and involve complex delivery systems, placing a substantial burden on patients both physically and financially. Inhalable dry powder formulations incorporating nanoparticles are emerging as superior alternatives due to their ease of use, stability, and long-term effectiveness. This advanced drug delivery system demonstrates improved efficacy and reduced dosage requirements for lung-related disorders. Key advantages include enhanced penetration into lung tissues, targeted deposition in specific lung regions, improved solubility, increased bioavailability, storage stability, and a high degree of customization. These formulations typically utilize finely milled or freeze-dried nanoparticles. The rise of novel respiratory infections, such as COVID-19, and the rapid development of nanoparticle-based vaccines have further spotlighted the potential of these technologies. Among the various aerosol delivery systems available, dry powder inhalers (DPIs) stand out as a preferred method for delivering nanoparticles to the respiratory tract. Over the past two decades, the success of dry powder inhalation therapies has inspired further exploration into their use for systemic diseases. While challenges remain, the potential of these therapies to revolutionize treatment options for systemic disorders remains immense.